Overview
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
Status:
Completed
Completed
Trial end date:
2010-12-01
2010-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
PfizerCollaborator:
Alzheimer's Disease Cooperative Study (ADCS)
Criteria
Inclusion Criteria:- Mini Mental State Exam (MMSE) score between 14-26 (inclusive) at screening.
- Participants must be receiving acetylcholinesterase inhibitors on a stable dose for at
least 4 months prior to randomization
Exclusion Criteria:
- Current evidence or history of neurological, psychiatric and any other illness that
could contribute to non-Alzheimer's dementia.
- Known history of familial AD or any evidence for early onset AD known or possibly
associated with genetic mutations.
- Evidence or history of diabetes mellitus Type 1 or Type 2.
- History or symptoms of autoimmune disorders.